PLoS ONE (Jan 2020)

Population-based trends in hospitalizations due to injection drug use-related serious bacterial infections, Oregon, 2008 to 2018.

  • Jeffrey Capizzi,
  • Judith Leahy,
  • Haven Wheelock,
  • Jonathan Garcia,
  • Luke Strnad,
  • Monica Sikka,
  • Honora Englander,
  • Ann Thomas,
  • P Todd Korthuis,
  • Timothy William Menza

DOI
https://doi.org/10.1371/journal.pone.0242165
Journal volume & issue
Vol. 15, no. 11
p. e0242165

Abstract

Read online

BackgroundInjection drug use has far-reaching social, economic, and health consequences. Serious bacterial infections, including skin/soft tissue infections, osteomyelitis, bacteremia, and endocarditis, are particularly morbid and mortal consequences of injection drug use.MethodsWe conducted a population-based retrospective cohort analysis of hospitalizations among patients with a diagnosis code for substance use and a serious bacterial infection during the same hospital admission using Oregon Hospital Discharge Data. We examined trends in hospitalizations and costs of hospitalizations attributable to injection drug use-related serious bacterial infections from January 1, 2008 through December 31, 2018.ResultsFrom 2008 to 2018, Oregon hospital discharge data included 4,084,743 hospitalizations among 2,090,359 patients. During the study period, hospitalizations for injection drug use-related serious bacterial infection increased from 980 to 6,265 per year, or from 0.26% to 1.68% of all hospitalizations (PConclusionsIn Oregon, hospitalizations for injection drug use-related serious bacterial infections increased dramatically and exacted a substantial cost on the health care system from 2008 to 2018. This increase in hospitalizations represents an opportunity to initiate substance use disorder treatment and harm reduction services to improve outcomes for people who inject drugs.